Integra LifeSciences (NASDAQ:IART) Stock Price Up 4.5% - Here's What Happened

Key Points

• Integra LifeSciences' stock price rose 4.5% during mid-day trading, reaching $14.69, despite a significant decline in trading volume compared to the average.
• Recent analyst reports have downgraded the company's stock price targets significantly, with ratings ranging from "Buy" to "Sell," leading to an average target price of $18.63.
• Integra LifeSciences reported earnings per share of $0.45 for the last quarter, exceeding estimates, but showed a revenue decline of 0.6% compared to the previous year.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s share price rose 4.5% during mid-day trading on Tuesday . The company traded as high as $14.70 and last traded at $14.69. Approximately 544,413 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 1,024,711 shares. The stock had previously closed at $14.05.

Wall Street Analyst Weigh In

IART has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Finally, JMP Securities reduced their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Reduce" and an average target price of $18.63.

Integra LifeSciences Stock Performance

The firm's fifty day moving average price is $12.66 and its 200-day moving average price is $16.65. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -2.25, a PEG ratio of 0.80 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. The firm had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. Integra LifeSciences's quarterly revenue was down .6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Large investors have recently bought and sold shares of the business. Arizona State Retirement System raised its position in Integra LifeSciences by 4.2% in the first quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock worth $437,000 after acquiring an additional 795 shares in the last quarter. Wedge Capital Management L L P NC raised its position in Integra LifeSciences by 1.2% in the second quarter. Wedge Capital Management L L P NC now owns 70,114 shares of the life sciences company's stock worth $860,000 after acquiring an additional 801 shares in the last quarter. Envestnet Asset Management Inc. raised its position in Integra LifeSciences by 4.6% in the first quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company's stock worth $605,000 after acquiring an additional 1,204 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Integra LifeSciences by 8.0% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,159 shares of the life sciences company's stock worth $211,000 after acquiring an additional 1,278 shares in the last quarter. Finally, Sei Investments Co. raised its position in Integra LifeSciences by 7.4% in the first quarter. Sei Investments Co. now owns 20,351 shares of the life sciences company's stock worth $451,000 after acquiring an additional 1,398 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.